Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age

Iana H. Haralambieva, Inna G. Ovsyannikova, Richard B. Kennedy, Krista M. Goergen, Diane E. Grill, Min hsin Chen, Lijuan Hao, Joseph Icenogle, Gregory A. Poland

Research output: Contribution to journalArticle

Abstract

In the U.S., measles, mumps, and rubella vaccination is recommended as two vaccine doses. A third dose of measles-mumps-rubella (MMR) vaccine is being administered in certain situations (e.g., identified seronegativity and during outbreaks). We studied rubella-specific humoral immunity (neutralizing antibody, enzyme-linked immunosorbent assay/ELISA IgG titer and antibody avidity) and the frequencies of antigen-specific memory B cells before and after a third dose of MMR-II in 109 female participants of childbearing age (median age, 34.5 years old) from Olmsted County, MN, with two documented prior MMR vaccine doses. The participants were selected from a cohort of 1117 individuals if they represented the high and the low ends of the rubella-specific antibody response spectrum. Of the 109 participants, we identified four individuals (3.67% of all study participants; 7.14% of the low-responder group) that were seronegative at Baseline (rubella-specific ELISA IgG titers <10 IU/mL), suggesting a lack of protection against rubella before receipt of a third MMR vaccine dose. The peak geometric mean neutralizing antibody titer one month following the third dose of MMR vaccine for the cohort was 243 NT50 (CI; 241, 245), which is expected for a cohort with two doses of MMR, and the peak geometric mean IgG titer was 150 IU/mL (CI; 148, 152) with no seronegative individuals at Day 28. One-third of all subjects (31.8% for the neutralizing antibody; 30.8% for the IgG titer) experienced a significant boost (≥4-fold) of antibody titers one month following vaccination. Antibody titers and other tested immune-response variables were significantly higher in the high-responder group compared to the low-responder group. The frequencies of rubella-specific memory B cells were modestly associated with the antibody titers. Our study suggests the importance of yet unknown inherent biologic and immune factors for the generation and maintenance of rubella-vaccine-induced humoral immune responses.

Original languageEnglish (US)
JournalVaccine
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Rubella virus
Measles-Mumps-Rubella Vaccine
Rubella
Humoral Immunity
humoral immunity
vaccines
Mumps
dosage
Measles
Immunoglobulin G
Neutralizing Antibodies
neutralizing antibodies
antibodies
Enzyme-Linked Immunosorbent Assay
enzyme-linked immunosorbent assay
B-lymphocytes
Antibodies
Vaccination
B-Lymphocytes
Rubella Vaccine

Keywords

  • Antibody
  • Humoral
  • Immunity
  • Measles-Mumps-Rubella Vaccine
  • Rubella
  • Rubella Vaccine
  • Viral

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age. / Haralambieva, Iana H.; Ovsyannikova, Inna G.; Kennedy, Richard B.; Goergen, Krista M.; Grill, Diane E.; Chen, Min hsin; Hao, Lijuan; Icenogle, Joseph; Poland, Gregory A.

In: Vaccine, 01.01.2019.

Research output: Contribution to journalArticle

Haralambieva, Iana H. ; Ovsyannikova, Inna G. ; Kennedy, Richard B. ; Goergen, Krista M. ; Grill, Diane E. ; Chen, Min hsin ; Hao, Lijuan ; Icenogle, Joseph ; Poland, Gregory A. / Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age. In: Vaccine. 2019.
@article{ec59490471614418bd18af9d64214d06,
title = "Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age",
abstract = "In the U.S., measles, mumps, and rubella vaccination is recommended as two vaccine doses. A third dose of measles-mumps-rubella (MMR) vaccine is being administered in certain situations (e.g., identified seronegativity and during outbreaks). We studied rubella-specific humoral immunity (neutralizing antibody, enzyme-linked immunosorbent assay/ELISA IgG titer and antibody avidity) and the frequencies of antigen-specific memory B cells before and after a third dose of MMR-II in 109 female participants of childbearing age (median age, 34.5 years old) from Olmsted County, MN, with two documented prior MMR vaccine doses. The participants were selected from a cohort of 1117 individuals if they represented the high and the low ends of the rubella-specific antibody response spectrum. Of the 109 participants, we identified four individuals (3.67{\%} of all study participants; 7.14{\%} of the low-responder group) that were seronegative at Baseline (rubella-specific ELISA IgG titers <10 IU/mL), suggesting a lack of protection against rubella before receipt of a third MMR vaccine dose. The peak geometric mean neutralizing antibody titer one month following the third dose of MMR vaccine for the cohort was 243 NT50 (CI; 241, 245), which is expected for a cohort with two doses of MMR, and the peak geometric mean IgG titer was 150 IU/mL (CI; 148, 152) with no seronegative individuals at Day 28. One-third of all subjects (31.8{\%} for the neutralizing antibody; 30.8{\%} for the IgG titer) experienced a significant boost (≥4-fold) of antibody titers one month following vaccination. Antibody titers and other tested immune-response variables were significantly higher in the high-responder group compared to the low-responder group. The frequencies of rubella-specific memory B cells were modestly associated with the antibody titers. Our study suggests the importance of yet unknown inherent biologic and immune factors for the generation and maintenance of rubella-vaccine-induced humoral immune responses.",
keywords = "Antibody, Humoral, Immunity, Measles-Mumps-Rubella Vaccine, Rubella, Rubella Vaccine, Viral",
author = "Haralambieva, {Iana H.} and Ovsyannikova, {Inna G.} and Kennedy, {Richard B.} and Goergen, {Krista M.} and Grill, {Diane E.} and Chen, {Min hsin} and Lijuan Hao and Joseph Icenogle and Poland, {Gregory A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.vaccine.2019.11.004",
language = "English (US)",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age

AU - Haralambieva, Iana H.

AU - Ovsyannikova, Inna G.

AU - Kennedy, Richard B.

AU - Goergen, Krista M.

AU - Grill, Diane E.

AU - Chen, Min hsin

AU - Hao, Lijuan

AU - Icenogle, Joseph

AU - Poland, Gregory A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In the U.S., measles, mumps, and rubella vaccination is recommended as two vaccine doses. A third dose of measles-mumps-rubella (MMR) vaccine is being administered in certain situations (e.g., identified seronegativity and during outbreaks). We studied rubella-specific humoral immunity (neutralizing antibody, enzyme-linked immunosorbent assay/ELISA IgG titer and antibody avidity) and the frequencies of antigen-specific memory B cells before and after a third dose of MMR-II in 109 female participants of childbearing age (median age, 34.5 years old) from Olmsted County, MN, with two documented prior MMR vaccine doses. The participants were selected from a cohort of 1117 individuals if they represented the high and the low ends of the rubella-specific antibody response spectrum. Of the 109 participants, we identified four individuals (3.67% of all study participants; 7.14% of the low-responder group) that were seronegative at Baseline (rubella-specific ELISA IgG titers <10 IU/mL), suggesting a lack of protection against rubella before receipt of a third MMR vaccine dose. The peak geometric mean neutralizing antibody titer one month following the third dose of MMR vaccine for the cohort was 243 NT50 (CI; 241, 245), which is expected for a cohort with two doses of MMR, and the peak geometric mean IgG titer was 150 IU/mL (CI; 148, 152) with no seronegative individuals at Day 28. One-third of all subjects (31.8% for the neutralizing antibody; 30.8% for the IgG titer) experienced a significant boost (≥4-fold) of antibody titers one month following vaccination. Antibody titers and other tested immune-response variables were significantly higher in the high-responder group compared to the low-responder group. The frequencies of rubella-specific memory B cells were modestly associated with the antibody titers. Our study suggests the importance of yet unknown inherent biologic and immune factors for the generation and maintenance of rubella-vaccine-induced humoral immune responses.

AB - In the U.S., measles, mumps, and rubella vaccination is recommended as two vaccine doses. A third dose of measles-mumps-rubella (MMR) vaccine is being administered in certain situations (e.g., identified seronegativity and during outbreaks). We studied rubella-specific humoral immunity (neutralizing antibody, enzyme-linked immunosorbent assay/ELISA IgG titer and antibody avidity) and the frequencies of antigen-specific memory B cells before and after a third dose of MMR-II in 109 female participants of childbearing age (median age, 34.5 years old) from Olmsted County, MN, with two documented prior MMR vaccine doses. The participants were selected from a cohort of 1117 individuals if they represented the high and the low ends of the rubella-specific antibody response spectrum. Of the 109 participants, we identified four individuals (3.67% of all study participants; 7.14% of the low-responder group) that were seronegative at Baseline (rubella-specific ELISA IgG titers <10 IU/mL), suggesting a lack of protection against rubella before receipt of a third MMR vaccine dose. The peak geometric mean neutralizing antibody titer one month following the third dose of MMR vaccine for the cohort was 243 NT50 (CI; 241, 245), which is expected for a cohort with two doses of MMR, and the peak geometric mean IgG titer was 150 IU/mL (CI; 148, 152) with no seronegative individuals at Day 28. One-third of all subjects (31.8% for the neutralizing antibody; 30.8% for the IgG titer) experienced a significant boost (≥4-fold) of antibody titers one month following vaccination. Antibody titers and other tested immune-response variables were significantly higher in the high-responder group compared to the low-responder group. The frequencies of rubella-specific memory B cells were modestly associated with the antibody titers. Our study suggests the importance of yet unknown inherent biologic and immune factors for the generation and maintenance of rubella-vaccine-induced humoral immune responses.

KW - Antibody

KW - Humoral

KW - Immunity

KW - Measles-Mumps-Rubella Vaccine

KW - Rubella

KW - Rubella Vaccine

KW - Viral

UR - http://www.scopus.com/inward/record.url?scp=85075347367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075347367&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.11.004

DO - 10.1016/j.vaccine.2019.11.004

M3 - Article

C2 - 31732325

AN - SCOPUS:85075347367

JO - Vaccine

JF - Vaccine

SN - 0264-410X

ER -